- 61% of patients on high-dose (600 mg) ORKA-001 achieved PASI 100 at Week 16 vs. 0% for placebo (p<0.0001).
- 86% achieved PASI 90 and IGA 0/1 in the high-dose cohort with favorable safety consistent with IL-23p19 class.
- Phase 3 trial initiation remains on track for 1H 2027.
?? Positive AI Sentiment (+7.5 / 10)
Observed market reaction after signal
4h +15.20% · Peak +15.20%